FATE News and Press, Fate Therapeutics Inc.

2026-07-11 02:25:00 ET Quick one before the weekend. I want this on the record while it’s still early because I think the rotation just told us where it’s going, and by the time it’s obvious, we’ll be paying up for it.... Read the full article on Seekin...

2026-07-09 10:38:06 ET More on Fate Therapeutics Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade) Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignm...

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built with a Suite of Genetic Edits and Manufactured as a Uniform Drug Product to Su...

2026-07-08 11:54:44 ET Topline Summary and Update When last I left off with Fate Therapeutics ( FATE ) in May 2025, I lamented the challenges that the company was facing as they continued their pivot into CAR T-cell therapy for autoimmune disease in the context of a heavily depr...

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune d...

SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune d...

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire Issued on behalf of GT Biopharma, Inc. GT Biopharma, Inc. (NASDAQ: GTBP) says newly implemented AI-based tools are accelerating its drug discovery and enginee...

2026-06-26 16:59:21 ET More on State Street Health Care Select Sector SPDR ETF AI Revolutionizing Biopharma: Faster, Better, Cheaper Trump's Psychedelics Stance Reignites Sector - How Investors Can Benefit Merck's Bio-Techne buyout put Life Sciences sector in focus: ...

2026-06-24 06:04:09 ET Read the full article on Seeking Alpha For further details see: Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune d...